WHO Essential Medicines Library

           Search
   

   
 
 
meglumine iotroxate
Go back to Medicine List    

MODEL LIST INFORMATION
SECTION FORMULATION DISEASE/INDICATION RATIONALE FOR INCLUSION
14.02.00.00 Radiocontrast media Dosage form and strength

Solution: 5-8 g iodine in 100-250 ml.



ATC Code
V08AC02

Type of List
Complementary List

Ionic x-ray contrast medium.

Effective intravenous media for chelecstography and cholangiography.

Square box.

Date added: 1985.

MODEL FORMULARY INFORMATION
GENERAL INFORMATION

Meglumine iotroxate is a representative iodinated ionic dimeric contrast medium. Various media can serve as alternatives. It is a complementary drug

 

Uses: examination of the gallbladder and biliary tract

 

Contraindications: hypersensitivity to iodine-containing compounds

 

Precautions: history of allergy, atopy or asthma; severe hepatic impairment; renal impairment (Appendix 4); dehydration—correct fluid and electrolyte balance before administration; multiple myeloma (risk if dehydrated, may precipitate fatal renal failure); cardiac disease, hypertension, phaeochromocytoma, sickle-cell disease, hyperthyroidism, elderly, debilitated or children—increased risk of adverse effects; pregnancy; breastfeeding; may interfere with thyroid-function tests; biguanides (withdraw 48 hours before administration; restart when renal function stabilized); important: because of risk of hypersensitivity reactions, adequate resuscitation facilities must be immediately available during radiographic procedures

 

Dose: Examination of gallbladder and biliary tract, by intravenous injection, ADULT 100 ml of meglumine iotroxate 10.5% solution over at least 15 minutes (consult manufacturer’s literature)

 

ADMINISTRATION. Only by specialist radiographers, according to manufacturer’s directions

 

Adverse effects: nausea, vomiting, metallic taste, flushing, sensations of heat, weakness, dizziness, headache, cough, rhinitis, sweating, sneezing, lacrimation, visual disturbances, pruritus, salivary gland enlargement, pallor, cardiac disorders, haemodynamic disturbances and hypotension or hypertension; rarely, convulsions, paralysis, coma, rigors, arrhythmias, pulmonary oedema, circulatory failure and cardiac arrest; occasionally anaphylactoid or hypersensitivity reactions; hyperthyroidism; pain on injection; extravasation may result in tissue damage, thrombophlebitis, thrombosis, venospasm and embolism

 



MEDICINE REFERENCES